Background Abnormal liver enzymes are frequently encountered in inflammatory bowel disease (IBD) patients. Infliximab has been implicated in inducing drug-induced liver injury, autoimmune hepatitis or reactivation of hepatitis B virus. We aimed to clarify the role of infliximab in liver impairment in an IBD cohort. Study A total of 305 patients with IBD, without evidence of chronic liver disease, were included in the study and retrospectively evaluated. Laboratory and clinical data were retrieved from a prospectively acquired database. In all, 176 consecutive patients treated with infliximab during the last 5 years were compared with a matched population of 129 patients who did not receive any antitumour necrosis factor treatment. Results Elevation of alanine transaminase (ALT) was frequent in the entire population (36.4%) and it was not significantly associated with the use of infliximab (P = 0.284). Elevations more than 3 upper limit of normal were observed in 7.9% and these resolved spontaneously in 83%. The use of immunomodulators was the only factor that was significantly associated with liver enzyme abnormalities in multivariate analysis [odds ratio (OR) 2.666, 95% confidence interval (CI) 1.576-4.511, P < 0.005]. Overall, 39% of patients on infliximab had elevated liver enzymes and this was associated with increased ALT before starting infliximab (OR 3.854, 95% CI 1.800-8.251, P = 0.001) and with longer duration of infliximab treatment (OR 1.030, 95% CI 1.013-1.047, P = 0.001).
Introduction
Inflammatory bowel diseases (IBD), consisting mainly of Crohn's disease (CD) and ulcerative colitis (UC), are complex immune-mediated multifactorial gastrointestinal disorders [1] . Intestinal inflammation is a result of aberrant activation of T-cell response to commensal enteric flora in genetically susceptible hosts [2] . This chronic inflammatory process is characterized by periods of relapse and remission.
IBD therapy aims to induce and sustain remission as long as possible. Multiple therapeutic agents have been used for this purpose. Aminosalicylates, corticosteroids, thiopurines, methotrexate, cyclosporine and more recently tumour necrosis factor α (TNFα) antibodies have been proven to be efficient in inducing and maintaining clinical remission in patients with active CD or UC [3] .
However, most of these agents have been linked to some extent to hepatotoxicity. Almost all immunosuppressive regimens used in IBD have been reported to increase hepatic enzymes, sometimes necessitating drug discontinuation [4] .
Infliximab is a chimeric monoclonal antibody that binds avidly to TNFα, resulting in its inactivation. It is currently indicated for CD, UC and several rheumatologic disorders [5] . Infliximab was considered to be a safe medication in terms of liver impairment, even though it is known to result in asymptomatic elevation of liver enzymes [6] [7] [8] . Postmarketing reports, however, have shown that severe liver injury can be induced by this agent, resulting even in liver transplantation [9] .
The aim of this study was to define the true incidence of liver impairment related to infliximab in a real-life IBD cohort and to compare it with an IBD control group not receiving this medication. As a secondary endpoint, we attempted to correlate the alanine transaminase (ALT) levels with clinical events that could lead to potential discontinuation or change of treatment.
Materials and methods

Study population
All consecutive IBD patients treated with infliximab from 2008 to 2013 in the Department of Gastroenterology, Royal Free Hospital, London, were retrospectively evaluated. The diagnoses of CD and UC were established by standard clinical, radiological, histological and endoscopic criteria [10, 11] . Patients diagnosed with known liverrelated disease, such as primary sclerosing cholangitis (PSC) or chronic viral hepatitis, were excluded from the study. Laboratory parameters were obtained the day before infliximab induction as baseline and all subsequent follow-up blood tests (full blood count and liver enzymes) were recorded. Elevation of transaminases was categorized as mild, moderate or severe [ALT ≤ 2 upper limit of normal (ULN), ALT = 2-3 ULN and ALT ≥ 3 ULN, respectively]. In patients with elevated liver enzymes after infliximab, we retrospectively checked their liver biochemistry up to 1 year before baseline and we recorded any other events of liver impairment during that time. Data were retrieved from medical records for concomitant medications, especially those potentially related to hepatotoxicity (immunomodulators, aminosalicylates, antibiotics). Liver enzymes were recorded until each patient's last follow-up.
The same parameters were obtained from a control group of IBD patients, who did not receive any anti-TNF agent, and were matched by sex, type of IBD and duration of follow-up to the study group.
Definitions
Abnormality or increase in liver enzymes was defined as any elevation in ALT (ULN 33 U/l), aspartate transaminase (ULN 31 U/l), alkaline phosphatase (ALP ULN 129 U/l), γ-glutamyl transferase (ULN 36 U/l) and/or bilirubin (ULN 21 μmol/l). Elevation of transaminases was defined as mild in ALT ≤ 2 ULN, moderate in ALT × 2-3 ULN and significant in ALT ≥ 3 ULN. The R value was calculated as the ratio (ALT/ALT ULN : ALP/ALP ULN). R greater than or equal to 5 corresponds to a hepatocellular pattern of drug-induced liver injury (DILI), R less than or equal to 2 to a cholestatic pattern and R between 2 and 5 is defined as a mixed type of DILI [12] .
Treatment
All patients treated with infliximab were receiving the standard regimen dose of 5 mg/kg at weeks 0, 2, 6 and every 8 weeks thereafter [13] . The total duration of treatment in months was recorded. The use of azathioprine, 6-mercaptopurine (6-MP), methotrexate, aminosalicylates and steroids was recorded when they were prescribed during the period of the study. Full blood count and liver biochemistry were monitored every 8 weeks for patients on infliximab and every 3-6 months for the rest of the population.
Statistical analysis
Data were expressed as mean and SD for continuous and normally distributed variables, median and range for continuous variables without a normal distribution or frequencies (%) for categorical variables. For comparisons, the χ 2 -test was used for categorical variables; the Student's t-test and the Mann-Whitney test were used for continuous variables with or without a normal distribution, respectively. For comparisons between more than two groups, the Kruskal-Wallis test was applied. Univariate analysis was used to identify parameters associated with abnormal ALT. Multiple logistic regression was used for multivariate analysis. The level of statistical significance was set at P less than or equal to 0.05. Statistical analysis was carried out using the Statistical Package for Social Sciences, version 22 (SPSS Inc., Chicago, Illinois, USA).
Results
Patients' characteristics
A total of 176 IBD patients were treated with infliximab between 2008 and 2013 and fulfilled the inclusion criteria for the study. As a control group, 129 IBD patients out of the total IBD population treated in the Gastroenterology Department were selected. In total, 305 patients with IBD were included in the study. Thirteen patients were evaluated and excluded because of other liver-related diseases: five with concomitant PSC, three with hepatitis C virus, one with established cirrhosis and four with active cytomegalovirus (CMV) viraemia.
The mean age of the patients was 40 14.7 years and 164 were men (53.8%). A total of 223/305 patients (73%) had CD and 82 patients had UC. The mean duration of infliximab treatment was 23.1 21.7 months.
Cumulative percentages for the use of each drug during the 5-year follow-up were infliximab 57.7%, azathioprine 40.7%, 6-MP 13.1%, aminosalicylates 21% and steroids 7.2%. These are summarized in Table 1 .
Abnormal liver enzymes in the infliximab population
A total of 176/305 patients (57.7%) were treated with infliximab and ALT increase was observed in 69 (39.2%) of them, with spontaneous resolution in 76% of cases. The mean age of the patients was 37.8 14.1 years; 105/176 (59.7%) were men and 138/176 (80%) had CD. All patients had been checked for hepatotropic viruses before initiation of infliximab (hepatitis A virus, hepatitis B virus, hepatitis C virus, CMV, Epstein-Barr virus, varicellazoster virus). Nearly half of them were taking immunomodulators, that is, azathioprine, 6-MP or methotrexate. Of the 69 patients who received infliximab; the mean duration of treatment was 23.1 21.7 months and 31 (44.9%) showed an elevation of ALT within the first 3 months of treatment and 41 (59%) had at least one episode of elevated liver enzymes 1 year before ( Table 2) . Thirty-seven (53.6%) patients underwent autoimmune testing when abnormal liver tests were found and 12 (32%) had positive antinuclear antibodies (ANA), but with low titres (< 1 : 80) and normal immunoglobulins. These 69 patients were compared with the rest of the infliximab subpopulation that did not have any ALT abnormality during the period of the study (n = 107). No statistically significant difference was found among age (P = 0.654), sex (P = 0.152), diagnosis (UC or CD, P = 0.219) and use of immunomodulators, aminosalicylates or steroids between the two groups (P = 0.235, 0.713 and 0.699, respectively). A total of 25/69 (36.2%) of patients with ALT abnormalities after infliximab induction also had at least one episode of elevated ALT up to 1 year before compared with 16/107 (15%) of those with normal liver enzymes after infliximab treatment (P = 0.002). The mean duration of anti-TNF treatment was 29.5 months in patients with abnormal liver enzymes, and this was significantly longer compared with patients with normal liver biochemistry; the mean duration of infliximab treatment was 11.5 months (P < 0.0005) ( Table 3) .
In multivariate analysis, abnormal ALT in the subgroup of patients treated with infliximab was significantly associated with elevated ALT before infliximab induction [odds ratio (OR) 3.854, 95% confidence interval (CI) 1.800-8.251, P = 0.001] and longer duration of infliximab treatment (OR 1.030, 95% CI 1.013-1.047, P = 0.001).
Abnormal liver enzymes in the entire cohort A total of 111/305 patients (36.4%) were found to have at least one episode of elevated liver enzymes, which resolved spontaneously in 73% of cases. Time to resolution was less than 3 months in 43% of these patients. Thirty-eight patients with prolonged time to resolution (48%) had only mildly abnormal transaminases (< 2 ULN), possibly reflecting a nonacute aetiology such as fatty liver disease. The elevation was moderate in 10.2% and severe in 7.9% of cases. Transaminases were predominantly elevated compared with cholestatic enzymes in the majority of patients (89.2%). Twelve patients (10.8%) had a preponderance of elevated cholestatic enzymes (ALP, γ-glutamyl transferase).
We compared patients with normal ALT (194/305) with those with at least one ALT abnormality since entry into the study (111/305). There was no significant difference in age (P = 0.134), sex (P = 0.165), IBD diagnosis (UC or CD, P = 0.262), anti-TNF treatment (P = 0.284) and use of aminosalicylates or steroids between the two groups (P = 0.487 and 0.240, respectively). A total of 85/111 (76.6%) patients with abnormal ALT were taking immunomodulators compared with 105/194 (43.9%) with normal ALT; this was statistically significant (P = 0.001). The correlation of immunomodulators to ALT abnormalities was also confirmed in multivariate analysis (OR 2.666, 95% CI 1.576-4.511, P < 0.001), whereas use of infliximab, steroids or aminosalicylates, age, sex and diagnosis were not statistically significant (P = NS) ( Table 4 ). 
Patients with significant liver injury
Twenty-four patients out of the entire cohort (24/305, 7.9%) had an ALT more than three times the ULN and 12 (50%) of them were treated with infliximab. All except one (95%) had CD. All were screened for hepatitis A virus, hepatitis B virus, hepatitis C virus and CMV serology and found to be negative. The rest of the liver screening tests, such as immunoglobulin G, ferritin, α1-antitrypsin, copper and ceruloplasmin levels, were tested and found to be normal. A total of 4/24 patients (16.6%) had positive ANA (3/4 on anti-TNF). Thirteen (54.1%) of those with significant liver injury were receiving some immunomodulatory agent. Ultrasound and/or computed tomography (CT) of the liver was performed in the majority of patients, showing fatty liver in 10 (41.6%), other lesions such as gallstones or haemangiomata in four (16.6%) and normal findings in six (25%) ( Table 5 ).
All except one patient under infliximab had a hepatocellular type of damage with an R value greater than 5. A cholestatic pattern of liver injury was found in four patients not on anti-TNF treatment. Magnetic resonance cholangiopancreatography was performed in those with elevated cholestatic enzymes and there was no bile duct dilation or evidence of PSC.
A liver biopsy was performed in four patients (16.6%), three of whom were treated with infliximab. Liver histopathology indicated a probable DILI in 3/4 patients and nonalcoholic steatohepatitis in the other. Of the three patients with established DILI, one was on azathioprine, one on infliximab (which was discontinued) and one on a combination of infliximab and 6-MP (6-MP was subsequently discontinued).
ALT values normalized in 20/24 patients (83.3%). Out of the four patients with no spontaneous resolution of their abnormal ALT, one was in the infliximab group. Fatty infiltration of the liver was the cause of abnormal ALT (as confirmed by CT imaging) in two patients with persistent liver enzyme elevations and these patients were recommended lifestyle changes and close monitoring. No obvious reason for an intermittently elevated ALT despite extensive investigation was found in the other two patients.
Resolution occurred in 21/24 (87.5%) patients without discontinuation of IBD treatment. Infliximab was stopped in two patients: one with a biopsy showing DILI and one because of the absence of response who was switched to adalimumab. Azathioprine was discontinued in one patient with a biopsy-proven DILI.
Discussion
Hepatobiliary manifestations in patients with IBD are relatively frequent [14] . In our study, we confirmed the increased prevalence of elevated liver enzymes in an IBD population and we found that this is not associated with infliximab treatment. Furthermore, we showed that these elevations are usually not severe and they resolve spontaneously in the majority of cases, thus rarely requiring specific management.
Liver disease in IBD can develop because of an immunemediated pathogenetic mechanism as a complication of structural and pathophysiological changes because of IBD or from drug-induced hepatotoxicity [15] .
Several liver conditions have been frequently associated with IBD, the most common being PSC. Almost 80% of patients diagnosed with PSC have IBD and a percentage of up to 7% of IBD patients will finally develop PSC [5] . Autoimmune hepatitis more often occurs in UC patients than in the general population [16] . Cholelithiasis is more common in CD patients than in matched controls and this is associated with bile salt absorption affected by the number of surgeries and extent of ileal resections [17] . Patients with IBD are also prone to thrombosis [18] . Portal or hepatic vein thrombosis can lead to portal hypertension and liver cirrhosis. Nonalcoholic fatty liver disease appears to be more common in IBD patients, with prevalence as high as 35% [17] .
Medications used for IBD treatment are highly associated with hepatotoxicity. Thiopurines can result not only in asymptomatic liver enzyme elevation but also in DILI or even liver injury because of the generation of reactive oxygen species through oxidation of azathioprine or 6-MP by xanthine oxidase [19] . Thiopurine methyltransferase is the enzyme that catalyses 6-MP methylation and shows considerable variation in its activity because of multiple genetic polymorphisms. As a result, toxic metabolites such as 6-methylmercaptopurine can accumulate in some patients, leading to a greater extent of liver impairment [20] . Moreover, azathioprine has been linked to nodular regenerative hyperplasia of the liver and noncirrhotic portal hypertension [12] . The prevalence of 6-MP-induced and azathioprine-induced liver impairment varies in several studies. In a recent study of 3931 IBD patients, 95% of whom were on azathioprine, the incidence of hepatotoxicity was 4% [13] . Earlier studies have reported a higher incidence of abnormal liver enzymes in IBD patients treated with thiopurines (10-20%) [21, 22] . 5-Aminosalicylate is probably the responsible hepatotoxic moiety of aminosalicylates. Abnormal hepatic biochemistry attributed to these agents has been described since 1989 [14] . The hepatotoxic potential of methotrexate was first recorded in patients treated for psoriasis several decades ago. However, few trials have been conducted in IBD patients so far. In a meta-analysis of 13 trials, Khan et al. [15] showed that liver injury induced by methotrexate occurs at an incidence comparable to that of thiopurines. Infliximab was initially approved for the treatment of moderate to severe CD and rheumatoid arthritis in 1998 [23] . Most serious side effects include an increase in the frequency of infections, allergic reactions and generation of autoantibodies (mostly antinuclear and double-stranded DNA). Elevation of liver enzymes is relatively common because of infliximab, but significant liver damage was considered to be extremely rare [24] .
Several case reports have been published reporting hepatitis, frequently immune-mediated, that occurred after infliximab induction and resolved after discontinuation of the drug [25] [26] [27] [28] . In a recent study, Ghabril et al. [9] described 34 cases of DILI induced by anti-TNFs. Most of them follow a hepatocellular pattern of injury, have an autoimmune background and resolve after discontinuation of treatment. Switching infliximab to adalimumab seems to be well tolerated, suggesting the absence of crosstoxicity between the two agents [29] .
Reactivation of occult hepatitis B can result in liver impairment and it was first described in two rheumatologic patients that were treated with infliximab in 2003 [30, 31] .
In the ATTRACT study group, 23 and 16%, respectively, of patients receiving infliximab for rheumatoid arthritis developed ANA and anti-double-stranded DNA antibodies versus 6 and 0% of placebo recipients [32] . Autoimmune hepatitis may accompany the positivity of autoantibodies with markedly elevated transaminases and a typical liver biopsy showing interface hepatitis with lymphoplasmacytic infiltrate [33] .
Infliximab may induce elevation of liver enzymes because of an idiosyncratic drug reaction. Jaundice is a rare finding and in most cases, liver impairment resolves spontaneously.
Overall, infliximab may result in liver abnormalities through different mechanisms, raising issues in terms of its safety. An Austrian consensus on infliximab use in IBD after 10 years on the market proposes discontinuation of treatment in cases of significant liver enzyme elevations (>3 ULN) [7] .
In our study, the prevalence of abnormal liver enzymes was remarkably high: almost 40%. However, a similarly high incidence of elevated liver tests has been reported before [34, 35] . In the majority of our population, the elevation was mild to moderate and only a few patients developed ALT ≥3 ULN. Even significant elevations tended to resolve without need for treatment discontinuation. Immunomodulatory agents were the only significant predictors of abnormal ALT, a correlation reported previously [21, 22] . It is noteworthy that this association was not statistically significant in the infliximab population.
The incidence of increased transaminases in our study was similar in both infliximab-treated and non-infliximabtreated populations. Infliximab could possibly be associated with some cases of ALT abnormalities, but these were mostly mild. Even with significantly increased aminotransferases, the outcome was favourable and treatment was discontinued in only one patient. The presence of abnormal ALT before infliximab induction was significantly related to abnormal ALT in postinfliximab measurements, emphasizing that several conditions unrelated to anti-TNF therapy may impair the hepatobiliary parameters in IBD. Moreover, the presence of significant ALT elevations before infliximab initiation should trigger a liver screen to identify pre-existing liver disease.
Another interesting finding was that the duration of infliximab therapy was significantly associated with elevated liver enzymes. This group of patients requiring anti-TNF therapy for longer is usually unresponsive to conventional treatment, with longer periods of relapse and hospitalizations. Continuously active IBD may be responsible for a proportion of these liver abnormalities. Ascertainment bias is another possible explanation for this finding as these patients are monitored more frequently than those with a disease with an indolent course.
The main limitation of this study is that, because of its retrospective design, imaging procedures and liver biopsy were not performed in the entire cohort. It is noteworthy that 41% of patients with a significant elevation of hepatic enzymes turned out to have a fatty liver in ultrasound or CT scans. Liver biopsy was also performed in a minority of patients (4/111 patients, 3.6%).
Conclusion
Elevation of liver enzymes in IBD is not uncommon, but is usually mild and transient, resolving spontaneously in the majority of cases. Even significant abnormalities resolved spontaneously in more than two-thirds of cases. These abnormalities are likely to be multifactorial. Treatment with infliximab was not associated with abnormal ALT in our study, suggesting that this agent is generally safe. ALT elevation should not necessarily dictate discontinuation of treatment; however, investigations should be performed to identify the exact diagnosis and underlying liver disease should be excluded in patients treated with infliximab. Other possible aetiologies should be considered in cases of persistent or significant ALT abnormalities and priority should be given to stopping immunomodulators first rather than infliximab. A liver biopsy can establish the diagnosis in patients with persistent unexplained transaminase elevation and guide further therapeutic decisions, particularly in terms of the continuation of immunomodulators and/or infliximab.
We therefore recommend a wait-and-watch strategy rather than immediate action in IBD patients with elevated liver enzymes. A liver biopsy would be of most importance in these cases that do not spontaneously resolve to obtain the correct diagnosis. Infliximab could be maintained, except for those cases of established and biopsy-proven DILIs, when thiopurines are excluded as the main cause of liver function test abnormalities or of significant unexplained ALT elevations.
The optimal time point to decide on further management in significant ALT elevations has not yet been clarified. In our study, resolution occurred usually within the first 3 months, but this is not universal. Further prospective studies and histopathologic evaluation of similar populations could expand our knowledge of this common phenomenon. Moreover, the presence of other liver-related aetiologies, such as nonalcoholic fatty liver disease, should always influence the final decision.
